Business Context and Reporting Period
Company: OrthoPediatrics Corp. (Ticker: KIDS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 5, 2024
Reporting Period: Immediate event reporting regarding the entry into material definitive agreements on August 5, 2024.
Key Financial Metrics and Capital Structure
This filing details a significant recapitalization event rather than operational financial results. Key metrics include:
- Term Loan Facility: Initial principal of $25.0 million with a delayed draw term loan (DDTL) option of up to an additional $25.0 million.
- Convertible Notes: $50.0 million aggregate principal amount of 4.75% Convertible Senior Notes due February 15, 2030.
- Interest Rates:
- Term Loans: SOFR + 6.50% (with a 3.25% floor) plus an optional 1.00% payment-in-kind (PIK) interest.
- Convertible Notes: 4.75% per annum, payable quarterly.
- Stock Repurchase Authorization: Up to $5.0 million.
- Debt Maturity: Term Loans mature August 5, 2029; Convertible Notes mature February 15, 2030.
Material Changes and Transaction Details
The Company entered into two primary financing agreements on August 5, 2024:
- Term Loan Agreement:
- Secured by a first priority security interest in substantially all assets, including intellectual property.
- Interest-only payments until maturity; no amortization.
- Prepayment fees range from 3.00% (first 12 months) to 0.00% (after 36 months), plus a 2.00% exit fee.
- Covenants include maintaining unrestricted cash equal to at least 25% of outstanding Term Loans and minimum net product sales.
- Convertible Senior Notes:
- Senior, unsecured obligations.
- Initial conversion price: Approximately $40.98 per share (24.4021 shares per $1,000 principal).
- Convertible at holder's election after November 15, 2029, or earlier upon specific fundamental changes or trading price thresholds.
- Redeemable by the Company on or after February 21, 2028, if stock price exceeds 140% of the conversion price.
Use of Proceeds, Guidance, and Risks
Use of Proceeds:
- Repayment of existing debt (approximately $10.0 million).
- Payment of transaction fees (approximately $6.5 million for Notes; additional fees for Term Loan).
- Up to $5.0 million for common stock repurchases.
- Working capital and general corporate purposes.
The Company approved a stock repurchase program contingent on the closing of these financings. The filing includes standard forward-looking statements regarding the risks of the transactions not closing as expected.
Risks and Contingencies:- Covenants: Strict financial covenants regarding cash balances and net product sales.
- Prepayment Penalties: Significant fees apply to early repayment of the Term Loan.
- Dilution: Up to 1,691,470 shares of common stock may be issued upon conversion of the Notes.
- Default Risks: Events of default include failure to make payments, bankruptcy, or breach of covenants, which could lead to acceleration of debt obligations.
Investor Verification Checklist
- Verify the closing date and actual funding amounts of the Term Loan and Convertible Notes.
- Confirm the current SOFR rate to calculate the effective interest cost on the Term Loan.
- Review the Company's current unrestricted cash balance to ensure compliance with the 25% collateral covenant.
- Monitor the Company's stock price relative to the $40.98 conversion price and the 140% redemption threshold.
- Check subsequent filings for the execution of the $5.0 million stock repurchase program.